Published on
The treatment modifies a domain in the CAR that targets CD19, making it look more human and therefore less likely to be rejected by patients.
Published on
CHOP researchers were interviewed as a part of a comprehensive article about cell and gene therapy in Philadelphia Magazine.
Published on
Dr. Shannon Maude, an attending physician in the Cancer Center at CHOP, provided expert insight on the unique challenges facing CAR T-cell therapy for pediatric indications in an article published in Healio’s February issue of Cell Therapy Next.
Published on
The results of the study could help to identify patients with AML who do not respond well to chemotherapy and may instead benefit from novel immunotherapy.
Published on
Latest news including elections to NAM, cures for picky eaters, lawn mower injuries and more.
Published on
The $200,000 award will fund research to develop a novel therapeutic that ignites the immune system and could act as a stand-alone treatment, as well as boost the effectiveness of existing immunotherapies.
Published on
CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.
Published on
Families make long journeys — and even relocate — so their children can receive specialized treatment at CHOP.
Published on
Stephan Grupp, MD, PhD, Chief of the Cell Therapy and Transplant Section in the Division of Oncology, has been elected into the National Academy of Medicine (NAM).
Published on
The National Academy of Medicine elects two global leaders in cellular and gene therapy from Children’s Hospital of Philadelphia.